Eli Lilly Vs. Novo Nordisk: One Stock Is Massively Undervalued, The Other Overvalued

Despite recent stock declines for both Eli Lilly and Novo Nordisk amidst GLP-1 market competition and patent considerations, analysis suggests a valuation disparity. Novo Nordisk is presented as severely undervalued, projecting up to 77% upside given its lower required growth rate to justify current valuation and significant future potential in Alzheimer's treatment with Semaglutide. Conversely, Eli Lilly appears slightly overvalued. The assessment concludes Novo Nordisk is a strong buy, while Eli Lilly is a hold.

Analysis

An analysis of Eli Lilly (LLY) and Novo Nordisk (NVO) reveals a significant valuation disparity despite both companies experiencing recent sell-offs in the burgeoning GLP-1 market. While both generate approximately 20% of revenue from obesity drugs, NVO's stock has declined ~61% from its peak, far steeper than LLY's ~25% drop. According to a discounted cash flow model presented, LLY's $629 billion market capitalization implies a required annual growth rate of 18% through 2032, which appears stretched against a calculated achievable growth of 15.8%, suggesting an 11% overvaluation. In stark contrast, NVO's $241 billion valuation requires only 1% annual growth post-2025, while a conservative forecast indicates achievable growth of 11.3%, pointing to a potential 77% undervaluation. This valuation gap persists despite NVO's shorter patent runway in key markets like Canada and China (expiring 2026) compared to LLY's US patent protection until at least 2039. A critical factor for NVO is the significant upside optionality from its Phase 3 trial of Semaglutide for Alzheimer's disease, which could unlock a new multi-billion dollar market and is not fully priced in. The competitive landscape, including Roche's promising Phase 2 drug, and geopolitical risks from potential US trade tariffs, contribute to market volatility but appear to have disproportionately impacted NVO's valuation.

Key Decisions for Investors

• Given the analysis suggesting a potential 77% undervaluation for Novo Nordisk, investors may consider the stock a compelling opportunity, factoring in the low growth rate required to justify its current price and the significant upside from its Alzheimer's drug pipeline.
• For Eli Lilly, which appears slightly overvalued with a high 18% required growth hurdle, current holders might consider trimming their positions, while prospective buyers should exercise caution and could await a price correction of approximately 10% for a more attractive entry point.
• Investors should closely monitor the patent expiration timelines, as NVO's earlier expirations starting in 2026 pose a medium-term risk, whereas LLY's longer protection until 2039 offers greater revenue visibility in the US market.
• Closely track clinical trial data from both companies and key competitors like Roche, as efficacy, side effect profiles, and pricing will remain primary drivers of stock volatility and market share shifts in the competitive weight-loss drug segment.